Growth Metrics

IGC Pharma (IGC) Receivables - Net (2016 - 2025)

IGC Pharma has reported Receivables - Net over the past 15 years, most recently at $41000.0 for Q3 2025.

  • Quarterly Receivables - Net fell 6.82% to $41000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $41000.0 through Sep 2025, down 6.82% year-over-year, with the annual reading at $34000.0 for FY2025, 12.82% down from the prior year.
  • Receivables - Net was $41000.0 for Q3 2025 at IGC Pharma, down from $87000.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $251000.0 in Q4 2022 and troughed at $28000.0 in Q2 2024.
  • The 5-year median for Receivables - Net is $125000.0 (2022), against an average of $117578.9.
  • Year-over-year, Receivables - Net plummeted 87.56% in 2024 and then skyrocketed 210.71% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $164000.0 in 2021, then surged by 53.05% to $251000.0 in 2022, then tumbled by 63.35% to $92000.0 in 2023, then crashed by 46.74% to $49000.0 in 2024, then dropped by 16.33% to $41000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Receivables - Net are $41000.0 (Q3 2025), $87000.0 (Q2 2025), and $34000.0 (Q1 2025).